Sunesis Pharmaceuticals, Inc

(NASDAQ:SNSS)

Latest On Sunesis Pharmaceuticals, Inc (SNSS):

Date/Time Type Description Signal Details
2021-02-26 16:21 ESTFinancialsCompany financials have been released.Neutral
2021-02-26 04:41 ESTAnalyst RatingThe Analyst Target Price has increased from $6.17 to $21.58.Buy
2021-02-25 04:56 ESTEarnings EstimateAn EPS average of -$0.42 is estimated for the 2022 year.Sell
2021-02-25 04:56 ESTEarnings EstimateAn EPS average of -$0.16 is estimated for the quarter ending on June 30, 2021.Buy
2021-02-24 14:31 ESTNewsSunesis Pharma continues momentum after Q4 earnings beat consensusN/A
2021-02-24 04:45 ESTAnalyst RatingThe Analyst Target Price has increased from $3.25 to $6.17.Buy
2020-12-07 10:31 ESTNewsSunesis rises 1.9% after Viracta sees registration trial in H1 for lymphoma regimenN/A
2020-12-02 04:09 ESTNewsSunesis Pharma to merge with Viracta Therapeutics in all-stock dealN/A
2020-11-26 21:36 ESTFinancialsCompany financials have been released.Neutral
2020-11-18 13:21 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 19:52 ESTNewsSunesis Pharmaceuticals EPS beats by $0.06N/A
2020-11-17 19:51 ESTNewsSunesis Pharmaceuticals, Inc. (SNSS) Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-17 05:26 ESTEarnings EstimateAn EPS average of -$0.14 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-08 00:56 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 17:10 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 14:04 ESTFinancialsCompany financials have been released.Neutral
2020-09-18 13:38 ESTAnalyst RatingThe Analyst Target Price has decreased from $7.5 to $3.25.Neutral
2020-09-17 06:17 ESTFinancialsCompany financials have been released.Neutral
2020-09-06 13:31 ESTAnalyst RatingThe Analyst Target Price has increased from $0.75 to $7.5.Buy
2020-09-04 01:41 ESTStock SplitA stock split has occured on Sep 3, 2020 with a split factor of 1:10.Neutral
2020-09-03 01:39 ESTNewsSunesis Pharmaceuticals to reverse split shares 1:10N/A
2020-08-29 10:44 ESTNewsSeeking Alpha Catalyst WatchN/A
2020-08-14 10:09 ESTFinancialsCompany financials have been released.Neutral
2020-08-13 09:45 ESTFinancialsCompany financials have been released.Neutral
2020-08-11 23:50 ESTNewsSunesis Pharmaceuticals EPS in-lineN/A
2020-08-11 23:50 ESTNewsSunesis Pharmaceuticals, Inc. (SNSS) CEO Dayton Misfeldt on Q2 2020 Results - Earnings Call TranscriptN/A
2020-08-06 13:57 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 17:52 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 05:52 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 04:50 ESTNewsSunesis Pharma readies equity offeringN/A
2020-07-30 04:49 ESTNewsSunesis under pressure on equity offeringN/A
2020-07-27 13:48 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 18:29 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 10:01 ESTFinancialsCompany financials have been released.Neutral
2020-07-07 18:47 ESTNewsSunesis Pharma announces 30% cut in headcountN/A
2020-07-07 01:39 ESTAnalyst RatingThe Analyst Target Price has decreased from $2.5 to $0.75.Neutral
2020-07-01 17:48 ESTFinancialsCompany financials have been released.Neutral
2020-06-23 12:10 ESTNewsSunesis Pharma plunges 45% on vecabrutinib setbackN/A
2020-06-19 13:41 ESTFinancialsCompany financials have been released.Neutral
2020-06-19 00:46 ESTNewsSunesis Pharma +10% on planned reverse splitN/A
2020-06-14 05:44 ESTFinancialsCompany financials have been released.Neutral
2020-06-12 06:10 ESTFinancialsCompany financials have been released.Neutral
2020-06-05 15:32 ESTInsider TradeTina Gullotta has directly acquired 6,000 shares and currently holds 20,500 shares.Buy
2020-06-02 01:46 ESTAnalyst RatingThe Analyst Target Price has decreased from $2.67 to $2.5.Neutral
2020-06-02 01:46 ESTEarnings EstimateAn EPS average of -$0.06 is estimated for the quarter ending on September 30, 2020.Sell
2020-05-27 06:17 ESTFinancialsCompany financials have been released.Neutral
2020-05-21 01:51 ESTFinancialsCompany financials have been released.Neutral
2020-05-10 21:09 ESTNewsSunesis Pharmaceuticals, Inc. (SNSS) CEO Dayton Misfeldt on Q1 2020 Results - Earnings Call TranscriptN/A
2020-05-10 09:37 ESTFinancialsCompany financials have been released.Neutral
2020-05-09 09:16 ESTNewsSunesis Pharmaceuticals EPS beats by $0.02, misses on revenueN/A

About Sunesis Pharmaceuticals, Inc (SNSS):

As of February 24, 2021, Sunesis Pharmaceuticals, Inc. was acquired by Viracta Therapeutics, Inc., in a reverse merger transaction. Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

SNSS Quotes by TradingView

See Advanced Chart

General

  • Name Sunesis Pharmaceuticals, Inc
  • Symbol SNSS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Last Split Factor1:10
  • Last Split Date2020-09-03
  • Fiscal Year EndDecember
  • IPO Date2005-09-27
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.sunesis.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 29.96
  • Price/Book (Most Recent Quarter) 5.09
  • Enterprise Value Revenue 2642.31
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.78
  • Next Year EPS Estimate -$1.47
  • Next Quarter EPS Estimate -$0.15
  • Operating Margin -18586%
  • Return on Assets -46%
  • Return on Equity -91%
  • Revenue 120000
  • Earnings Per Share -$0.48
  • Revenue Per Share $0.01
  • Gross Profit 120000
  • Quarterly Earnings Growth -100%
View More

Highlights

  • Market Capitalization 96.33 million
  • EBITDA -23921000
  • PEG Ratio -0.01
  • Analyst Target Price $21.58
  • Book Value Per Share $0.79
View More

Share Statistics

  • Shares Outstanding 18.11 million
  • Shares Float 13.76 million
  • % Held by Insiders 11%
  • % Held by Institutions 40.16%
  • Shares Short 1.22 million
  • Shares Short Prior Month 1.61 million
  • Short Ratio 0.99
  • Short % of Float 2%
  • Short % of Shares Outstanding 6%
View More

Technicals

  • Beta 2.23
  • 52 Week High $22.99
  • 52 Week Low $3.92
  • 50 Day Moving Average 11.39
  • 200 Day Moving Average 7.07
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Sunesis Pharmaceuticals, Inc (SNSS) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Sunesis Pharmaceuticals, Inc (SNSS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-24$N/A-$0.21-$0.9678.18%
2020-09-302020-11-16$N/A-$0.29-$1.3578.57%
2020-06-302020-08-11$N/A-$0.60-$1.9368.83%
2020-03-312020-05-07$N/A-$0.50-$2.4579.59%
2019-12-312020-03-10$2.07 million-$0.50-$2.6380.95%
2019-09-302019-11-12$N/A-$0.60-$2.9879.83%
2019-06-302019-08-07$N/A-$0.90-$3.5074.29%
2019-03-312019-05-08$N/A-$1.00-$6.0483.44%
2018-12-312019-03-07$237000-$1.60-$7.4478.49%
2018-09-302018-11-05$N/A-$1.80-$7.7076.62%
2018-06-302018-08-07$-237000-$2.00-$8.9377.59%
2018-03-312018-05-08$237000-$2.10-$10.1579.31%
2017-12-312018-03-08$669000-$2.10-$8.7576%
2017-09-302017-11-02$N/A-$4.30-$12.9566.8%
2017-06-302017-07-27$-669000-$4.10-$26.6084.59%
2017-03-312017-05-08$669000-$4.70-$24.1580.54%
2016-12-312017-03-09$676000-$4.40-$15.8772.27%
2016-09-302016-11-03$610000-$6.20-$25.6775.84%
2016-06-302016-07-29$610000-$7.20-$21.7066.82%
2016-03-312016-05-05$640000-$7.20-$24.1570.19%
2015-12-312016-03-10$670000-$9.00-$8.65-3.99%
2015-09-302015-11-05$683000-$0.54-$0.9140.66%
2015-06-302015-07-30$854000-$0.72-$0.754%
2015-03-312015-05-05$854000-$0.78-$0.9316.13%
2014-12-312015-03-12$896000-$0.12-$1.1789.74%
2014-09-302014-11-10$854000-$1.50-$1.02-47.06%
2014-06-302014-08-05$1.99 million-$1.20-$1.01-18.81%
2014-03-312014-05-07$2 million-$1.56-$1.01-54.46%
2013-12-312014-03-06$1.99 million-$0.78-$1.1833.9%
2013-09-302013-11-12$1.99 million-$0.90-$1.2125.62%
2013-06-302013-07-29$1.99 million-$0.96-$1.2321.95%
2013-03-312013-05-09$1.99 million-$1.38-$1.17-17.95%
2012-12-312013-03-13$1.99 million-$1.20-$1.16-3.45%
2012-09-302012-11-08$265000-$2.22-$0.79-181.01%
2012-06-302012-08-09$1.5 million-$1.08-$1.2010%
2012-03-312012-05-15$N/A-$1.80-$1.10-63.64%
2011-12-312012-03-14$4 million-$1.14-$1.140%
2011-09-302011-11-14$1000000-$0.66-$1.0838.89%
2011-06-302011-08-11$N/A-$1.08-$0.92-17.39%
2011-03-312011-05-12$4 million$0.24-$0.84128.57%
2010-12-312011-03-29$6000-$1.38-$0.58-137.93%
2010-09-302010-10-28$-14000-$0.72-$0.720%
2010-06-302010-08-12$14000-$2.52-$1.44-75%
2010-03-312010-04-29$13000-$3.96-$4.328.33%
2009-12-312010-03-30$13000-$5.40-$5.583.23%
2009-09-302009-11-16$12000-$5.04-$5.406.67%
2009-06-302009-07-29$3.51 million-$51.48-$5.40-853.33%
2009-03-312009-04-01$224000-$7.20-$6.66-8.11%
2008-12-312009-03-31$12000-$7.20-$6.66-8.11%
2008-09-302008-11-04$511000-$7.56-$15.1750.16%
2008-06-302008-08-07$2.59 million-$14.04-$16.6315.57%
2008-03-312008-05-08$2.3 million-$10.08-$9.29-8.5%
2007-12-312008-03-11$2.05 million-$9.36-$8.88-5.41%
2007-09-302007-11-01$1.83 million-$11.52-$10.29-11.95%
2007-06-302007-08-02$3.27 million-$11.16-$11.835.66%
2007-03-312007-05-04$2.52 million-$11.52-$12.064.48%
2006-12-312007-03-09$1.96 million-$11.16-$11.936.45%
2006-09-302006-11-02$1.95 million-$10.80-$10.15-6.4%
2006-06-302006-08-10$6.71 million-$5.40-$10.0846.43%
2006-03-312006-05-04$3.1 million-$14.04-$10.44-34.48%
2005-12-312006-03-24$4.52 million-$9.00-$10.9217.58%
2005-09-302005-11-14$3.35 million-$16,244.76

Sunesis Pharmaceuticals, Inc (SNSS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Sunesis Pharmaceuticals, Inc (SNSS) Chart:

Sunesis Pharmaceuticals, Inc (SNSS) News:

Below you will find a list of latest news for Sunesis Pharmaceuticals, Inc (SNSS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Sunesis Pharmaceuticals, Inc (SNSS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Sunesis Pharmaceuticals, Inc (SNSS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924320018146/0000899243-20-018146-index.htm
2019-01-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924319001901/0000899243-19-001901-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924319005709/0000899243-19-005709-index.htm
2019-04-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924319009381/0000899243-19-009381-index.htm
2019-04-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924319009382/0000899243-19-009382-index.htm
2019-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924319018919/0000899243-19-018919-index.htm
2019-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924319018921/0000899243-19-018921-index.htm
2019-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924319018922/0000899243-19-018922-index.htm
2019-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924319018925/0000899243-19-018925-index.htm
2019-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924319018926/0000899243-19-018926-index.htm
2019-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924319018928/0000899243-19-018928-index.htm
2019-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924319018931/0000899243-19-018931-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924319019602/0000899243-19-019602-index.htm
2019-08-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924319021585/0000899243-19-021585-index.htm
2019-10-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924319024443/0000899243-19-024443-index.htm
2020-04-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924320009971/0000899243-20-009971-index.htm
2020-04-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924320009975/0000899243-20-009975-index.htm
2020-04-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924320009976/0000899243-20-009976-index.htm
2020-05-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924320012077/0000899243-20-012077-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924320015389/0000899243-20-015389-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924320018122/0000899243-20-018122-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924320018129/0000899243-20-018129-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924320018132/0000899243-20-018132-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924320018135/0000899243-20-018135-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924320018136/0000899243-20-018136-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924320018141/0000899243-20-018141-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924320018143/0000899243-20-018143-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000089924320018146/0000899243-20-018146-index.htm
2019-01-28SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000091957419000647/0000919574-19-000647-index.htm
2019-07-19SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000091957419004698/0000919574-19-004698-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000091957420001634/0000919574-20-001634-index.htm
2020-03-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000091957420002360/0000919574-20-002360-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000092189519000485/0000921895-19-000485-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000092189520000568/0000921895-20-000568-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000110465920021229/0001104659-20-021229-index.htm
2020-03-05SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000110465920029716/0001104659-20-029716-index.htm
2020-08-03SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000110465920089422/0001104659-20-089422-index.htm
2018-07-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000114420418037855/0001144204-18-037855-index.htm
2018-07-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000117911018009414/0001179110-18-009414-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000117911018009415/0001179110-18-009415-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000117911018009417/0001179110-18-009417-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000117911018009419/0001179110-18-009419-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000117911018009421/0001179110-18-009421-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000117911018009423/0001179110-18-009423-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000117911018009425/0001179110-18-009425-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000117911018009427/0001179110-18-009427-index.htm
2018-12-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000117911018013757/0001179110-18-013757-index.htm
2019-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000117911019000327/0001179110-19-000327-index.htm
2019-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000117911019000328/0001179110-19-000328-index.htm
2019-03-253Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000117911019004252/0001179110-19-004252-index.htm
2019-09-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1061027/000117911019010707/0001179110-19-010707-index.htm
2018-06-25424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1061027/000119312518202477/0001193125-18-202477-index.htm
2018-06-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000119312518202489/0001193125-18-202489-index.htm
2018-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000119312518204177/0001193125-18-204177-index.htm
2019-01-17424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1061027/000119312519011525/0001193125-19-011525-index.htm
2019-01-17424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1061027/000119312519011535/0001193125-19-011535-index.htm
2019-01-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000119312519013101/0001193125-19-013101-index.htm
2019-01-22424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1061027/000119312519013103/0001193125-19-013103-index.htm
2019-01-22424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1061027/000119312519013105/0001193125-19-013105-index.htm
2019-01-24SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000119312519016025/0001193125-19-016025-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000119312519039855/0001193125-19-039855-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000119312519040789/0001193125-19-040789-index.htm
2019-07-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000119312519191868/0001193125-19-191868-index.htm
2019-07-10424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1061027/000119312519191887/0001193125-19-191887-index.htm
2019-07-10424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1061027/000119312519191889/0001193125-19-191889-index.htm
2019-07-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000119312519192601/0001193125-19-192601-index.htm
2019-07-12424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1061027/000119312519192757/0001193125-19-192757-index.htm
2019-07-12424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1061027/000119312519192760/0001193125-19-192760-index.htm
2019-07-15SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000119312519194012/0001193125-19-194012-index.htm
2019-09-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000119312519249560/0001193125-19-249560-index.htm
2020-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000119312520025229/0001193125-20-025229-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000119312520038303/0001193125-20-038303-index.htm
2020-07-28424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1061027/000119312520201026/0001193125-20-201026-index.htm
2020-07-30424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1061027/000119312520204214/0001193125-20-204214-index.htm
2019-07-22SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000149315219010914/0001493152-19-010914-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000149315220002380/0001493152-20-002380-index.htm
2020-08-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000149315220014963/0001493152-20-014963-index.htm
2020-07-29SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000153561020000108/0001535610-20-000108-index.htm
2018-04-25DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1061027/000156459018009001/0001564590-18-009001-index.htm
2018-04-25DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1061027/000156459018009004/0001564590-18-009004-index.htm
2018-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459018011842/0001564590-18-011842-index.htm
2018-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1061027/000156459018011879/0001564590-18-011879-index.htm
2018-06-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459018015189/0001564590-18-015189-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459018019914/0001564590-18-019914-index.htm
2018-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1061027/000156459018020104/0001564590-18-020104-index.htm
2018-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459018026845/0001564590-18-026845-index.htm
2018-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1061027/000156459018026884/0001564590-18-026884-index.htm
2018-12-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459018030395/0001564590-18-030395-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459019000296/0001564590-19-000296-index.htm
2019-01-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459019000592/0001564590-19-000592-index.htm
2019-02-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459019001823/0001564590-19-001823-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459019006787/0001564590-19-006787-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1061027/000156459019006828/0001564590-19-006828-index.htm
2019-04-12DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1061027/000156459019011528/0001564590-19-011528-index.htm
2019-04-12DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1061027/000156459019011529/0001564590-19-011529-index.htm
2019-04-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459019013724/0001564590-19-013724-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459019017201/0001564590-19-017201-index.htm
2019-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1061027/000156459019017293/0001564590-19-017293-index.htm
2019-05-09S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1061027/000156459019018099/0001564590-19-018099-index.htm
2019-06-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459019021915/0001564590-19-021915-index.htm
2019-07-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459019024693/0001564590-19-024693-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459019030094/0001564590-19-030094-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1061027/000156459019030130/0001564590-19-030130-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459019042907/0001564590-19-042907-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1061027/000156459019042985/0001564590-19-042985-index.htm
2019-12-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459019045478/0001564590-19-045478-index.htm
2019-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459019046142/0001564590-19-046142-index.htm
2020-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459020000405/0001564590-20-000405-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459020000889/0001564590-20-000889-index.htm
2020-02-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459020004826/0001564590-20-004826-index.htm
2020-03-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459020008269/0001564590-20-008269-index.htm
2020-03-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459020009736/0001564590-20-009736-index.htm
2020-03-1010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1061027/000156459020009783/0001564590-20-009783-index.htm
2020-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459020011519/0001564590-20-011519-index.htm
2020-04-17PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1061027/000156459020017304/0001564590-20-017304-index.htm
2020-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459020018222/0001564590-20-018222-index.htm
2020-04-28DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1061027/000156459020019208/0001564590-20-019208-index.htm
2020-04-28DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1061027/000156459020019221/0001564590-20-019221-index.htm
2020-05-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459020020550/0001564590-20-020550-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459020022902/0001564590-20-022902-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1061027/000156459020022937/0001564590-20-022937-index.htm
2020-05-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1061027/000156459020023668/0001564590-20-023668-index.htm
2020-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459020029670/0001564590-20-029670-index.htm
2020-07-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459020033927/0001564590-20-033927-index.htm
2020-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459020034911/0001564590-20-034911-index.htm
2020-08-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459020039312/0001564590-20-039312-index.htm
2020-08-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1061027/000156459020039326/0001564590-20-039326-index.htm
2020-09-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459020042362/0001564590-20-042362-index.htm
2020-09-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1061027/000156459020044001/0001564590-20-044001-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000158064219000785/0001580642-19-000785-index.htm
2020-02-04SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000158064220000516/0001580642-20-000516-index.htm
2019-01-25SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1061027/000168788819000001/0001687888-19-000001-index.htm
2019-03-18CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1061027/999999999719001274/9999999997-19-001274-index.htm
2019-03-18CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1061027/999999999719001276/9999999997-19-001276-index.htm

Sunesis Pharmaceuticals, Inc (SNSS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Sunesis Pharmaceuticals, Inc (SNSS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 11%
Institutional Ownership: 4016%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-07-15Aisling Capital IV, LP10% Share HolderBuy2,500,000.000.601,500,000.0010,100,000.00https://www.sec.gov/Archives/edgar/data/1061027/000089924319019602/0000899243-19-019602-index.htm
2019-02-28William P. QuinnOfficerBuy63,697.00115,697.00https://www.sec.gov/Archives/edgar/data/1061027/000089924319005709/0000899243-19-005709-index.htm
2019-05-31William P. QuinnOfficerBuy6,000.000.653,876.60121,697.00https://www.sec.gov/Archives/edgar/data/1061027/000089924320009976/0000899243-20-009976-index.htm
2019-11-29William P. QuinnOfficerBuy6,000.000.372,193.00127,697.00https://www.sec.gov/Archives/edgar/data/1061027/000089924320009976/0000899243-20-009976-index.htm
2020-05-29Tina GullottaVP, FinanceBuy6,000.000.331,989.0020,500.00https://www.sec.gov/Archives/edgar/data/1061027/000089924320015389/0000899243-20-015389-index.htm
2018-12-10William P. QuinnCFO,Sr.V.P. Finance, Corp.Dev.Buy40,000.000.4718,800.0052,000.00https://www.sec.gov/Archives/edgar/data/1061027/000117911018013757/0001179110-18-013757-index.htm